BioLineRx and Hemispherian Bring GLIX1 Brain Cancer Research to SNO 2026

Key Points

• BioLineRx and Hemispherian will present two GLIX1 posters at the Society for Neuro-Oncology annual meeting in Philadelphia.
• Both presentations are scheduled for November 13, 2026, from 7:30–9:30 p.m. EST.
• One poster will cover preclinical findings across multiple glioblastoma models, including a temozolomide-resistant model.
• The second will describe the ongoing Phase 1/2a trial in recurrent or progressive high-grade glioma.
• The announcement does not provide human efficacy results, numerical preclinical findings or a clinical data-readout date.

BioLineRx (NASDAQ: BLRX) and Hemispherian will showcase their investigational cancer therapy GLIX1 at the 31st Society for Neuro-Oncology Annual Meeting & Education Day, taking place November 12–15 in Philadelphia. The presentations will address laboratory research and the design of the companies’ ongoing early-stage clinical study.

Preclinical Poster Examines GLIX1 in Glioblastoma Models

Dr. Adam Robertson, Hemispherian’s chief scientific officer, will present poster EXTH-31 on GLIX1’s antitumor activity across several glioblastoma models. The research includes orthotopic cell-derived models and a subcutaneous patient-derived model resistant to temozolomide, or TMZ.

GLIX1 is an oral, small-molecule TET2 activator targeting the DNA damage response. Although the poster title describes potent antitumor activity, the announcement does not include numerical findings. Results in preclinical models do not establish effectiveness in patients.

Clinical Poster Outlines Ongoing Phase 1/2a Trial

Dr. Ditte Primdahl of Northwestern University Feinberg School of Medicine will present poster CTNI-25 on the Phase 1/2a study of GLIX1 in recurrent or progressive high-grade glioma.

The clinical program, initiated in the first quarter of 2026, is evaluating GLIX1 in high-grade glioma and other solid tumors. The announced presentation focuses on trial design rather than reported treatment outcomes.

Both posters will be presented on November 13 from 7:30–9:30 p.m. EST in Exhibit Halls D and E at the Pennsylvania Convention Center.

GLIX1 Leads BioLineRx’s Development Pipeline

BioLineRx identifies GLIX1 as its lead development asset, advanced through its collaboration with Oslo-based Hemispherian.

Separately, BioLineRx’s approved product APHEXDA, or motixafortide, is indicated in the United States for stem-cell mobilization before autologous transplantation in multiple myeloma. BioLineRx has retained rights to develop motixafortide in solid tumors and has an ongoing Phase 2b pancreatic cancer study with Columbia University. APHEXDA’s approved use is distinct from GLIX1’s investigational program.

Investor Takeaway: Research Visibility, Not a Clinical Readout

For BioLineRx investors, the SNO presentations provide an opportunity to examine GLIX1’s preclinical rationale and clinical-study design. They do not constitute an announced human efficacy milestone.

The key future evidence will come from the Phase 1/2a trial. This release does not disclose patient outcomes, enrollment progress, a regulatory submission timetable or expected revenue from GLIX1.